Raf: a strategic target for therapeutic development against cancer.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Clinical Oncology

• Publication date

  2005-09-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1200/JCO.2005.08.036PMID 16170185
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Raf-1 protein expression in human breast cancer cells

  2006cited by this paper
• Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

  2005cited by this paper
• Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

  2005cited by this paper
• Results of a phase I trial of BAY 43-9006 in combination with oxaliplatin in patients with refractory solid tumors.

  2004cited by this paper
• A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer.

  2004cited by this paper
• BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience.

  2004cited by this paper
• Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma.

  2004cited by this paper
• BRAF mutations in acute leukemias

  2004cited by this paper
• Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT).

  2004cited by this paper
• Inflammatory breast carcinoma: the sphinx of breast cancer research.

  2004cited by this paper
• Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma

  2004cited by this paper
• Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.

  2003cited by this paper
• High frequency of BRAF mutations in nevi

  2003cited by this paper
• Raf proteins and cancer: B-Raf is identified as a mutational target.

  2003cited by this paper
• Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review).

  2003cited by this paper
• Rat mammary carcinogenesis induced by in situ expression of constitutive Raf kinase activity is prevented by tethering Raf to the plasma membrane.

  2003cited by this paper
• Connection between integrins and cell activation in rat adrenal glomerulosa cells: a role for Arg-Gly-Asp peptide in the activation of the p42/p44(mapk) pathway and intracellular calcium.

  2003cited by this paper
• BRAF mutation in papillary thyroid carcinoma.

  2003cited by this paper
• Mutations of the BRAF gene in squamous cell carcinoma of the head and neck

  2003cited by this paper
• Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs.

  2003cited by this paper
• A Raf-1 Mutant That Dissociates MEK/Extracellular Signal-Regulated Kinase Activation from Malignant Transformation and Differentiation but Not Proliferation

  2003cited by this paper
• Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116).

  2003cited by this paper
• A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors.

  2003cited by this paper
• BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.

  2003cited by this paper
• Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma

  2003cited by this paper
• Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation

  2003cited by this paper
• Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006.

  2003cited by this paper
• Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.

  2003cited by this paper
• Activity of the Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors.

  2003cited by this paper
• Clinical development of 17-allylamino, 17-demethoxygeldanamycin.

  2003cited by this paper
• Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.

  2003cited by this paper
• Antisense oligonucleotide therapy in cancer.

  2003cited by this paper
• Mechanisms of regulating the Raf kinase family.

  2003cited by this paper
• Role of Raf in Vascular Protection from Distinct Apoptotic Stimuli

  2003cited by this paper
• BRAF and KRAS mutations in stomach cancer

  2003cited by this paper
• BRAF mutations in non-Hodgkin's lymphoma

  2003cited by this paper
• High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.

  2003cited by this paper
• Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age.

  2003cited by this paper
• Synthesis and antitumor activity of novel O-carbamoylmethyloxime derivatives of radicicol.

  2003cited by this paper
• Lack of BRAF mutation in primary uveal melanoma.

  2003cited by this paper
• Dephosphorylation of Ser-259 Regulates Raf-1 Membrane Association*

  2002cited by this paper
• Tumor Regression by Targeted Gene Delivery to the Neovasculature

  2002cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• The Protein Kinase Complement of the Human Genome

  2002cited by this paper
• Regulation of Raf‐1 activation and signalling by dephosphorylation

  2002cited by this paper
• Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.

  2002cited by this paper
• A genome-based strategy uncovers frequent BRAF mutations in melanoma.

  2002cited by this paper
• Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status

  2002cited by this paper
• Associations of B- and C-Raf with Cholesterol, Phosphatidylserine, and Lipid Second Messengers

  2002cited by this paper
• Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors.

  2002cited by this paper
• BAY 43-9006: preclinical data.

  2002cited by this paper
• Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors.

  2002cited by this paper
• Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.

  2002cited by this paper
• BRAF and RAS mutations in human lung cancer and melanoma.

  2002cited by this paper
• A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.

  2002cited by this paper
• HSP90 as a new therapeutic target for cancer therapy: the story unfolds

  2002cited by this paper
• Pharmacological inhibitors of MAPK pathways.

  2002cited by this paper
• Activation of c-Raf Kinase by Ultraviolet Light

  2002cited by this paper
• Re: “Inhibition of medullary thyroid carcinoma (MTC) cell proliferation and RET phosphorylation by tyrosine kinase inhibitors”

  2002cited by this paper
• Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228.

  2002cited by this paper
• Tpl‐2 induces apoptosis by promoting the assembly of protein complexes that contain caspase‐9, the adapter protein Tvl‐1, and procaspase‐3

  2001cited by this paper
• Rap1 signalling: adhering to new models

  2001cited by this paper
• Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.

  2001cited by this paper
• The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.

  2001cited by this paper
• A prodrug approach to the design of cRaf1 kinase inhibitors with improved cellular activity.

  2001cited by this paper
• Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK–ERK independent mechanism

  2001cited by this paper
• Embryonic lethality and fetal liver apoptosis in mice lacking the c‐raf‐1 gene

  2001cited by this paper
• Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity.

  2001cited by this paper
• Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report.

  2001cited by this paper
• Positive and negative regulation of Raf kinase activity and function by phosphorylation

  2001cited by this paper
• Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade.

  2001cited by this paper
• KSR: a MAPK scaffold of the Ras pathway?

  2001cited by this paper
• Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis.

  2001cited by this paper
• Active Ras induces heterodimerization of cRaf and BRaf.

  2001cited by this paper
• Regulation of Raf by Akt Controls Growth and Differentiation in Vascular Smooth Muscle Cells*

  2001cited by this paper
• Serum- and Glucocorticoid-inducible Kinase SGK Phosphorylates and Negatively Regulates B-Raf*

  2001cited by this paper
• MEK kinase activity is not necessary for Raf‐1 function

  2001cited by this paper
• Thyrotropin activates mitogen-activated protein kinase pathway in FRTL-5 by a cAMP-dependent protein kinase A-independent mechanism.

  2001cited by this paper
• Discovery of a novel Raf kinase inhibitor.

  2001cited by this paper
• Erythropoietin-stimulated Raf-1 tyrosine phosphorylation is associated with the tyrosine kinase Lyn in J2E erythroleukemic cells.

  2001cited by this paper
• Cell cycle regulation by the Cdc25 phosphatase family.

  2000cited by this paper
• Isoform-Specific Localization of A-RAF in Mitochondria

  2000cited by this paper
• Activation of B‐Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601

  2000cited by this paper
• The Raf‐1 kinase associates with vimentin kinases and regulates the structure of vimentin filaments

  2000cited by this paper
• Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein.

  2000cited by this paper
• A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.

  2000cited by this paper
• Negative regulation of the serine/threonine kinase B-Raf by Akt.

  2000cited by this paper
• Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects.

  2000cited by this paper
• Phosphatidylinositol 3-kinase regulates Raf1 through Pak phosphorylation of serine 338.

  2000cited by this paper
• The discovery of potent cRaf1 kinase inhibitors.

  2000cited by this paper
• Cell-type specific integration of cross-talk between extracellular signal-regulated kinase and cAMP signaling.

  2000cited by this paper
• Raf induces NF-kappaB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation.

  2000cited by this paper
• Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions.

  2000cited by this paper
• Ras mediates the cAMP‐dependent activation of extracellular signal‐regulated kinases (ERKs) in melanocytes

  2000cited by this paper
• Regulation of the protein kinase Raf-1 by oncogenic Ras through phosphatidylinositol 3-kinase, Cdc42/Rac and Pak.

  2000cited by this paper
• Multiple Signaling Pathways of the Insulin-Like Growth Factor 1 Receptor in Protection from Apoptosis

  1999cited by this paper
• Raf‐1 and B‐Raf proteins have similar regional distributions but differential subcellular localization in adult rat brain

  1999cited by this paper
• Serine and tyrosine phosphorylations cooperate in Raf‐1, but not B‐Raf activation

  1999cited by this paper

• Impact of BRAF Gene Mutation in Nonmetastatic Colorectal Cancer on Disease Progression and Survival Outcomes

  2026cites this paper
• Prognostic analysis and expression patterns of programmed cell death ligand 1 and BRAF V600E in esophageal neuroendocrine carcinoma

  2025cites this paper
• The role of cerebrospinal fluid metabolites in the pathogenesis of lung adenocarcinoma: An observational study using Mendelian randomization.

  2025cites this paper
• In Silico Identification of Novel and Potent Inhibitors Against Mutant BRAF (V600E), MD Simulations, Free Energy Calculations, and Experimental Determination of Binding Affinity

  2025cites this paper
• Biomarkers for colorectal cancer detection: An insight into colorectal cancer and FDA-approved biomarkers

  2025cites this paper
• Prevalence, genetic variations and clinical outcomes of BRAF-V600 mutated advanced NSCLC in China: a retrospective real-world multi-centre study

  2025cites this paper
• Phytocompounds-based therapeutic approach: Investigating curcumin and green tea extracts on MCF-7 breast cancer cell line

  2024cites this paper
• Corynoxine exerts the anti-tumor effect on esophageal squamous cell carcinoma principally via the EZH2-DUSP5-ERK1/2-mediated cell growth inhibition.

  2024cites this paper
• Efficacy of chemo-immunotherapy in metastatic BRAF-mutated lung cancer: a single-center retrospective data

  2024cites this paper
• PU-H71 (NSC 750424): a molecular masterpiece that targets HSP90 in cancer and beyond

  2024cites this paper
• Histological evidence of MAPK pathway activation across subtypes of adult orbital xanthogranulomatous disease irrespective of the detection of oncogenic mutations.

  2024cites this paper
• Methods and biomarkers for early detection, prediction, and diagnosis of colorectal cancer.

  2023cites this paper
• An Efficient Suppression of EGFR and B-Raf mRNA Overexpression in the Lung of Benzo[a]pyrene-induced mice by Cationic Lipo-ATRA Nanoformulation.

  2023cites this paper
• Evaluation of BRAF v600 mutation by single strand conformation polymorphism-PCR (SSCP-PCR) in patients with interstitial lung disease

  2023cites this paper
• Investigation of the Antitumor Effects of Anti-inflammatory Desloratadine and Trimebutine on Different Types of Human Cancer Cells: An In Vitro study

  2023cites this paper
• E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers.

  2022cites this paper
• Metanephric adenoma: molecular study and review of the literature

  2022cites this paper
• Adult orbital xanthogranuloma: long-term follow-up of treated cases

  2022cites this paper
• Phytocompounds from Withania somnifera against breast cancer: An in-silico study

  2022cites this paper
• The Synergistic Cytotoxic Effects of GW5074 and Sorafenib by Impacting Mitochondrial Functions in Human Colorectal Cancer Cell Lines

  2022cites this paper
• In Silico Identification of Promising New Pyrazole Derivative-Based Small Molecules for Modulating CRMP2, C-RAF, CYP17, VEGFR, C-KIT, and HDAC—Application towards Cancer Therapeutics

  2022cites this paper
• Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneous Tumors

  2022cites this paper
• BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective

  2022cites this paper
• NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions

  2021cites this paper
• ERK: A Double-Edged Sword in Cancer. ERK-Dependent Apoptosis as a Potential Therapeutic Strategy for Cancer

  2021cites this paper
• Erdheim-Chester Disease: a comprehensive review from the ophthalmologic perspective.

  2021cites this paper
• Advances in pathogenesis and precision medicine for nasopharyngeal carcinoma

  2021cites this paper
• Cucurbitacin IIb induces apoptosis and cell cycle arrest through regulating EGFR/MAPK pathway.

  2020cites this paper
• Exploring Dysregulated Signaling Pathways in Cancer.

  2020cites this paper
• Sorafenib

  2020cites this paper
• 2-substituted benzothiazoles as antiproliferative agents: Novel insights on structure-activity relationships.

  2020cites this paper
• Mucinous borderline ovarian tumors with BRAFV600E mutation may have low risk for progression to invasive carcinomas

  2020cites this paper
• Fertility Outcomes and Sperm-DNA Parameters in Metastatic Melanoma Survivors Receiving Vemurafenib or Dabrafenib Therapy: Case Report

  2020cites this paper
• Intracellular Signaling

  2020cites this paper
• Validation of Immunohistochemistry for the Detection of BRAF V600E-Mutated Lung Adenocarcinomas

  2019cites this paper
• RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS.

  2019cites this paper
• Chemo-resistant Gastric Cancer Associated Gene Expression Signature: Bioinformatics Analysis Based on Gene Expression Omnibus

  2019cites this paper
• Advanced stage melanoma therapies: Detailing the present and exploring the future.

  2019cites this paper
• Molecular Targeted Therapy in the Management of Recurrent and Metastatic Nasopharyngeal Carcinoma: A Comprehensive Literature Review

  2019cites this paper
• Токсичність МАРК у карциномах щитоподібної залози. Механізми пригнічення сигнального каскаду (огляд літератури та власних даних)

  2019cites this paper
• Rapid BRAF Mutation Testing in Pigmented Melanomas.

  2019cites this paper
• BRAF: From Discovery to Drug Resistance

  2019influential citation
• Comparative interactome analysis reveals distinct and overlapping properties of Raf family kinases.

  2019cites this paper
• Characteristic And Novel Therapeutic Strategies Of Nasopharyngeal Carcinoma With Synchronous Metastasis

  2019cites this paper
• RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS.

  2019cites this paper
• CMAR_A_219994 8431..8442

  2019cites this paper
• Over-expression of miR-206 decreases the Euthyrox-resistance by targeting MAP4K3 in papillary thyroid carcinoma.

  2019cites this paper
• NCCN Guidelines Insights: Colon Cancer, Version 2.2018.

  2018cites this paper
• Metastatic malignancies and the effect on arterial stiffness and blood pressure levels: the possible role of chemotherapy

  2018cites this paper
• Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents.

  2018cites this paper
• Oncogene toxicity in thyroid carcinomas and other types of tumors

  2018cites this paper
• Exploring the efficacy and cellular uptake of sorafenib in colon cancer cells by Raman micro-spectroscopy.

  2018cites this paper
• Metastatic malignancies and the effect on arterial stiffness and blood pressure levels: the possible role of chemotherapy

  2018cites this paper
• Molecular Markers and Mutational Analysis

  2018cites this paper
• Colon Cancer , Version 2 . 2018 Featured Updates to the NCCN Guidelines

  2018cites this paper
• Update in Immunotherapies for Melanoma

  2018cites this paper
• BRIM‐P: A phase I, open‐label, multicenter, dose‐escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation‐positive melanoma

  2018cites this paper
• Patients with non-small-cell lung cancer harbouring a BRAF mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14.

  2018cites this paper
• Identification of recurrent USP48 and BRAF mutations in Cushing’s disease

  2018cites this paper
• [Erdheim-Chester disease (ECD), an inflammatory myeloid neoplasia].

  2017cites this paper
• Chemical proteomics for characterization of small molecule kinase inhibitors in cancer and inflammation

  2017cites this paper
• Expanded molecular interrogation for potential actionable targets in non-squamous non-small cell lung cancer.

  2017cites this paper
• Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives.

  2017cites this paper
• Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS

  2017cites this paper
• Acute motor and sensory axonal neuropathy related to treatment with MEK inhibitors in a patient with advanced melanoma.

  2017cites this paper
• A case report of ascending colon adenosquamous carcinoma with BRAF V600E mutation

  2017cites this paper
• Erdheim-Chester Disease and Other Histiocytoses

  2017cites this paper
• Using gene expression database to uncover biology functions of 1,4-disubstituted 1,2,3-triazole analogues synthesized via a copper (I)-catalyzed reaction.

  2017cites this paper
• MiR-199a-5p and let-7c cooperatively inhibit migration and invasion by targeting MAP4K3 in hepatocellular carcinoma

  2017cites this paper
• Role of mitogen-activated protein kinase (MAPK) in processes of proliferation in human thyroid tumors

  2016cites this paper
• Dual-targeting of MEK and CDK4/6 in KRAS-mutated Non-Small Cell Lung Cancer

  2016cites this paper
• Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma.

  2016cites this paper
• Contribution of complement anaphylatoxin receptors to melanoma growth: potential therapeutic targets

  2016cites this paper
• Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non–Small Cell Lung Cancers In Vitro and In Vivo

  2016cites this paper
• Phase II trial evaluating the efficacy of sorafenib (BAY 43‐9006) and correlating early fluorodeoxyglucose positron emission tomography–CT response to outcome in patients with recurrent and/or metastatic head and neck cancer

  2016cites this paper
• BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?

  2016cites this paper
• Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma

  2016cites this paper
• Recomendaciones para la determinación de biomarcadores en el melanoma metastásico. Consenso Nacional de la Sociedad Espade Anatomía Patológica y de la Sociedad Espade Oncología Médica

  2016cites this paper
• Expression and activity of extracellular signal-regulated kinase-1/2 (ERK1/2) in normal tissues and human thyroid tumors

  2016cites this paper
• The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib

  2016influential citation
• The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions

  2016cites this paper
• BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies.

  2015cites this paper
• Quantitative proteomics reveals the downregulation of GRB2 as a prominent node of F806-targeted cell proliferation network.

  2015cites this paper
• Mutational Analysis of BRAF InhibitoreAssociated Squamoproliferative

  2015cites this paper
• Targeting a chemorefractory COLO205 (BRAF V600E) cell line using substituted benzo[α]phenoxazines

  2015cites this paper
• BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma

  2015cites this paper
• The Expression and Activation of Extracellular Signal-Regulated Kinase-1/2 and Proliferating Cell Nuclear Antigen Content in Normal Tissue and Human Thyroid Tumors

  2015cites this paper
• The histiocytosis Erdheim–Chester disease is an inflammatory myeloid neoplasm

  2015cites this paper
• Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies

  2015cites this paper
• Multifaceted roles of HSF1 in cancer

  2015cites this paper
• Mutational Analysis of BRAF Inhibitor-Associated Squamoproliferative Lesions.

  2015cites this paper
• New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions

  2015cites this paper
• Broad targeting of resistance to apoptosis in cancer

  2015influential citation
• Biomarqueurs prédictifs de la réponse aux traitements par thérapies ciblées dans le cancer du sein

  2015cites this paper
• Activation of RAF1 (c-RAF) by the Marine Alkaloid Lasonolide A Induces Rapid Premature Chromosome Condensation

  2015cites this paper
• Pulmonary Langerhans cell histiocytosis: a comprehensive analysis of 40 patients and literature review.

  2015cites this paper
• The molecular mechanisms of a novel multi-kinase inhibitor ZLJ33 in suppressing pancreatic cancer growth.

  2015cites this paper
• Systemic Therapy in Metastatic Melanoma.

  2015cites this paper
• Recent progress in the identification of BRAF inhibitors as anti-cancer agents.

  2014cites this paper
• EXPLORING THE POSSIBLE ROLE OF C3aR LIGATION ON INTESTINAL EPITHELIAL CELLS

  2014cites this paper